FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens

Squamous cell lung cancer patients who have failed 1st or 2nd line systemic therapy for metastatic disease will be assigned based on FGFR1 status to the wild type and amplified groups. In the FGFR1 amplified group, the patients will be categorized in to "Low", "Intermediate", and "High" level of amplification. All patients will receive BIBF 1120 250 mg orally continuously twice daily for 28 days/cycle.

Study Number: 

I 225512

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.